Back to Search
CHRISTOPHER LOGOTHETIS, M.D.
M.D.
Medical Oncology Physician
NPI: 1477654721IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
F2328(TX)
CMS Specialties
PrimaryMEDICAL ONCOLOGY
Education
OTHER
Class of 1974
Research & Publications (20)
Understanding the biology of bone metastases: key to the effective treatment of prostate cancer.
PMID 18347159·Clin Cancer Res·2008
6-review
High-grade prostate cancer and the prostate cancer prevention trial.
PMID 19138948·Cancer Prev Res (Phila)·2008
8-other
Strategy for the application of therapy in prostate cancer.
PMID 18497043·Adv Exp Med Biol·2008
6-review
Foundation for the integration of biologically based therapy in the management of prostate cancer.
PMID 12886521·Prostate·2003
6-review
The case for a biologically based classification of prostate cancer.
PMID 14571406·Semin Oncol·2003
6-review
Docetaxel in the management of advanced or metastatic urothelial tract cancer.
PMID 12108893·Oncology (Williston Park)·2002
6-review
Docetaxel in the integrated management of prostate cancer. Current applications and future promise.
PMID 12108899·Oncology (Williston Park)·2002
6-review
Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer.
PMID 11350884·Clin Cancer Res·2001
5-case
The role of caveolin-1 in prostate cancer: clinical implications.
PMID 19581923·Prostate Cancer Prostatic Dis·2010
6-review
GWAS meets microarray: are the results of genome-wide association studies and gene-expression profiling consistent? Prostate cancer as an example.
PMID 19652704·PLoS One·2009
8-other
Candidate pathways and genes for prostate cancer: a meta-analysis of gene expression data.
PMID 19653896·BMC Med Genomics·2009
8-other
Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma.
PMID 19338544·BJU Int·2009
8-other
Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer.
PMID 19414670·J Clin Oncol·2009
3-trial
Prostate cancer: thalidomide for prostate cancer: is there progress?
PMID 19424170·Nat Rev Urol·2009
8-other
NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells.
PMID 19276258·Clin Cancer Res·2009
3-trial
Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer.
PMID 19244175·J Natl Cancer Inst·2009
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1515 HOLCOMBE BLVD, 77030-4009
HOUSTON, TX 77030 - Phone
- (713) 792-6161
Quick Facts
- NPI
- 1477654721
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 52
- Publications
- 20
Are you this provider?
Claim Your Profile